SUMMERVILLE, S.C.--(BUSINESS WIRE)--SCRA’s entrepreneurial program, SC Launch, Inc., recently finalized a $200,000 investment in Charleston-based Phi Life Sciences, a molecular diagnostic and laboratory service company that aims to help patients by reducing disease mortality and adverse drug reactions through affordable, state-of-the-art screening and diagnostic technologies.
Phi Life Sciences’ solutions focus on a bench-to-bedside concept, providing doctors and patients with cutting-edge screening and diagnostic tools that will find diseases in the earliest stage, thereby allowing for the most effective treatments and improving success rates.
The company has been an SC Launch Client Company since 2016 and is located at the SCRA MUSC Innovation Center in Charleston, SC. Their laboratory has been accredited by CLIA and CAP.
“Phi Life Sciences is excited to be a leader in growing the biotech industry in South Carolina,” said Sawan Hurst, CEO of Phi Life Sciences. “We are honored to be recognized by SC Launch and SCRA as a high growth company in this sector and appreciate the support that we have received from the State of South Carolina.”
The SC Launch program is SCRA’s entrepreneurial platform that provides mentoring, grants and investments to qualified, South Carolina companies in the Advanced Materials/Manufacturing, Information Technology and Life Sciences industries.
“The team at Phi Life Sciences is dedicated to creating novel biotech solutions that will revolutionize disease detection and treatment,” said Bob Quinn, SCRA Executive Director. “We are proud to be a part of their growth and look forward to their impact on the life science industry in South Carolina and beyond.”
About SCRA
http://www.scra.org/
Chartered
in 1983 by the State of South Carolina as a public, non-profit
corporation, SCRA fosters South Carolina’s Innovation Economy by
supporting entrepreneurs, enabling academic research and its
commercialization, and connecting industry to innovators.